89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...
FierceBiotech12d
Metsera eyes $289M IPO to fund phase 3 weight loss trial
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...
FierceBiotech28d
Obesity-focused Metsera files IPO just 9 months after emerging
MET-097i also demonstrated a half-life of about 15 to 16 days, which Metsera believes is the longest of any NuSH analog peptide in development and improves upon than the reported half-life of ...
manilatimes11d
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Goldman Sachs & Co. LLC, Leerink Partners and BofA Securities are acting as lead book-running managers and Cantor is acting ...
manilatimes10d
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
(GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the ...
Seeking Alpha25d
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
Not only was this FGF21 analog able to help reduce triglycerides ... one major problem in that endogenous FGF21 has a very short half-life. Thus, this would not actually work for therapeutic ...
Life Science Leader5d
Advancements In GLP-1 Analog Formulation Development: Overcoming Challenges In Oral Delivery
Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...
89bio seeks $250 million in public stock offering
SAN FRANCISCO - 89bio, Inc. (NASDAQ:ETNB), a biopharmaceutical company specializing in liver and cardiometabolic diseases with a current market capitalization of $1.05 billion, has initiated a public ...
ahajournals.org9d
Abstract TP17: Discovery and development of sovateltide, an endothelin-B receptor agonist to treat cerebral stroke patients
Sovateltide is a synthetic analog of ET-1 and has very high selectivity for ET ... In the phase I clinical trial, conducted in healthy individuals, sovateltide had a short half-life of about 5 minutes ...
IGN29d
A tweet, a dog, and the number 197.
Half-Life fans have waited years for Valve to do… something Half-Life 3 related. That’s nothing new. But recent weeks have seen a step up in the hunt for clues, with some believing Valve has ...
The Atlantic8d
Why Contemporary Fiction Loves Analog Tech
She starts to learn about family events that have long been buried—things even her mother doesn’t know—only when she finds a trove of analog heirlooms: diaries, letters, and an old point-and ...